Navigation Links
Participants in antidepressant drug trials are atypical patients, UT Southwestern researchers report
Date:5/12/2009

DALLAS May 13, 2009 One reason antidepressant medication treatments do not work as well in real life as they do in clinical studies could be the limited type of study participants selected, researchers at UT Southwestern Medical Center have found.

"We are basing our judgment of clinical care in the United States on samples of patients that are totally different from the patient population actually treated in primary care and mental health facilities," said Dr. Madhukar Trivedi, professor of psychiatry at UT Southwestern and senior author of a study published in the May issue of the American Journal of Psychiatry. "Antidepressants should not be seen as a panacea. The general belief is that they work well, but they are less effective in real-world practice, and more work is needed."

As part of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study scientists found that only 22 percent of the 2,855 participants treated with a commonly prescribed antidepressant would have met the criteria for inclusion in a typical antidepressant efficacy trial. Those who did meet criteria had shorter bouts of depression, quicker response to medication, less severe side effects and fewer adverse events compared with those people with depression who would have been excluded from such a trial, used to gain Food and Drug Administration approval of the drugs used.

The STAR*D trial was the first large-scale study to define the effectiveness of several treatment steps in primary care and mental health settings for people with depression, Dr. Trivedi said.

The six-year, $35 million STAR*D study is the largest investigation on the treatment of major depressive disorder and is considered a benchmark in the field of depression research. It initially included more than 4,000 people from outpatient treatment sites across the country. About 65 percent of STAR*D participants, however, had a medical co-morbidity such as diabetes that typically would have excluded them from participating in other clinical trials to test the efficacy of antidepressants, said Dr. Trivedi, co-principal investigator of STAR*D.

"Evidence is growing that depression is like other chronic medical illnesses where it's not just one small, short bout, but a longer battle. People with depression may be at higher risk for other illnesses including obesity or diabetes, yet people with these conditions are excluded from drug trials for depression," Dr. Trivedi said.

STAR*D provided evidence for step-by-step guidelines to address treatment-resistant depression. Many treatment-resistant depression patients would be excluded from drug efficacy trials because those trials typically eliminate study candidates who have previously tried treatment, have suicidal thoughts or have other psychiatric illnesses.

"These are the patients impacted by depression the most highest suicide potential, highest unemployment rates, highest social impairment and they are likely to produce poorer outcomes," Dr. Trivedi said. "That population doesn't get studied systematically in traditional pharmaceutical industry studies."

More research involving patients routinely seen in clinical practice coupled with pharmacogenetics is sorely needed to better understand how to best match patients with specific antidepressant treatments, Dr. Trivedi said.

He recommended that clinicians continue to prescribe antidepressants but with more realistic expectations about the disease's long-term nature. Dr. Trivedi said researchers should design future trials in real clinical practice settings where patients have co-morbidities, as he is doing in his current research.


'/>"/>

Contact: Lakisha Ladson
lakisha.ladson@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. Help Raise Awareness of Obesity - Annual Walk From Obesity Invites Participants to Join a Walk in Their Local Area
2. AdvaMed 2007 Exceeds Attendance Expectations With More Than 1,100 Participants from 35 States and 25 Countries
3. Knowing doctors financial interests doesnt deter clinical trial participants
4. im Initiative Participants Select UNICEF as Top Charity in First Year of Microsofts Initiative
5. USP announces 2008 summer internship program participants
6. Medical research should include more women participants and examine the role of gender in disease
7. Medical Research Should Include More Women Participants and Examine the Role of Gender in Disease Incidence and Treatment
8. 23rd AIDS Walk Boston Draws Five-Year Record-Setting 20,000+ Participants, Doubles Runners to 600 and Raises $1.2 Million
9. 19th Annual Susan G. Komen National Race for the Cure(R) Draws Nearly 50,000 Participants, Celebrities; Brings Record Funds to National Capital Area
10. Fight Against Breast Cancer Receives Big Boost During Susan G. Komen Detroit Race for the Cure(R) With 344 Participants From Binsons, Northwood
11. 25,000 AIDS Walk San Francisco Participants; 25,000 Reasons Why
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... 23, 2017 , ... Drs. Allen Huang and Jeffrey Wang, ... Las Vegas, NV, and the importance of treating it immediately. They are now ... for peri-implantitis, with or without a referral. As experienced periodontists and implant specialists, ...
(Date:5/23/2017)... ... May 23, 2017 , ... Diagnotes, an Indianapolis-based digital ... feature on its secure clinical communication platform. The platform allows clinicians to easily ... the type and urgency of a situation. , “We know from our ...
(Date:5/23/2017)... ... May 23, 2017 , ... Orbita’s Nathan Treloar will discuss the role of ... Francisco. Titled Connected Health and IoT: Technology Innovators and Disruption , the workshop ... Associates, a market research and consulting firm specializing in emerging consumer technology products and ...
(Date:5/23/2017)... ... 23, 2017 , ... New patients looking for an alternative ... or without a referral, from the multi-specialty Dr. Smile practice. Dr. Esther Feldman ... in providing patients with the custom, convenient and long-lasting orthodontic treatment that helps ...
(Date:5/23/2017)... Mt. Horeb, WI (PRWEB) , ... May 23, 2017 , ... ... now invited to call Dr. Angela Cotey’s practice to schedule an appointment, with or ... dentistry services, and frequently offers pulpotomy treatments to pediatric patients as a healthy alternative ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... Fix Inc. (" Fortuna "), a private, clinical-stage biotech ... need for embryonic and fetal stem cells by using direct ... Fortuna announced today the launch of its Scientific ... PhD; Father Kevin FitzGerald , S.J., PhD; Col. (R) ... Giordano , PhD. "We are excited and honored ...
(Date:5/4/2017)... , May 4, 2017  DarioHealth Corp. (NASDAQ: ... health and big data solutions, today announced that it ... Company, and STI Technologies Limited to lower diabetes healthcare ... Through STI,s innoviCares card, which is available throughout all ... DarioHealth customers will be eligible for additional savings when ...
(Date:5/3/2017)... ROCKVILLE, Md. , May 3, 2017 /PRNewswire/ ... revenue growth of nine percent next year and ... solid organ and hematopoietic stem cell (HSCT) or ... and donor. Molecular testing technologies are well-suited for this ... healthcare-only market research publisher Kalorama Information. The various ...
Breaking Medicine Technology: